India Launches Blood Test for 10 Cancers, Boosting Early Detection

In a significant advancement for cancer diagnostics in India, Zydus Lifesciences and Apollo Hospitals have partnered to introduce the Shield Multi-Cancer Detection (MCD) blood test, designed to screen for signals associated with 10 common cancers through a single blood draw. This collaboration marks a crucial step towards making cancer detection simpler and less invasive for the Indian populace. The Shield MCD test, developed by US-based precision oncology company Guardant Health, utilizes advanced genomic technology and artificial intelligence to analyze methylation patterns—cancer-related changes in DNA circulating in the bloodstream. This methylation-based blood test is intended for eligible adults aged 45 years and above who are considered at average risk of developing cancer. The 10 specific cancers that the Shield MCD test screens for include bladder, breast, colorectal, liver, lung, oesophageal, gastric, ovarian, pancreatic, and prostate cancers. Many of these cancers are among the deadliest in India due to late detection, making early screening paramount. Apollo Cancer Centres (ACCs) has become the first healthcare institution in India to offer access to this test, following a Memorandum of Understanding (MoU) with Zydus Lifesciences. This launch is expected to significantly expand access to innovative multi-cancer screening technology across the country. Reports also suggest that Delhi-based Dr. Dang's Lab is looking to start offering the test nationwide, further broadening its availability. It is critical to understand that while the Shield MCD test is a promising screening tool, it is designed to complement, not replace, existing conventional screening methods such as mammography or colonoscopy. Doctors and researchers consistently emphasize that a positive result from the Shield MCD test does not definitively confirm a cancer diagnosis. Instead, it indicates the presence of cancer-associated signals and necessitates further diagnostic investigations, such as scans or biopsies, to confirm the presence and location of cancer. Conversely, a negative result does not completely rule out the risk of cancer, underscoring the importance of routine medical evaluations and symptom monitoring. India faces a substantial and growing cancer burden. Official estimates indicate that more than 1.41 million people were diagnosed with cancer in 2022, and over 900,000 succumbed to the disease. Cancer accounts for nearly nine percent of all deaths related to non-communicable diseases in the country. Breast cancer remains the leading cause of cancer-related mortality among women, while oral cancer is the most common cancer among men. Despite these alarming statistics, cancer screening rates in India remain low and uneven across various regions, highlighting an urgent need for more accessible and less invasive screening options like the Shield MCD test. The Shield MCD test has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for eight cancer types. This designation acknowledges the test's potential to provide more effective screening compared to existing options, based on its performance in studies like the National Cancer Institute Vanguard Study. However, it is important to note that this designation does not constitute full FDA approval or clearance for commercial sale or use in the U.S., as the Shield MCD test is currently classified as a laboratory-developed test intended for export. While the introduction of such advanced screening technology is a cause for optimism, the cost of the Shield MCD test in India is yet to be disclosed. Previous discussions around multi-cancer early detection (MCED) tests in India have highlighted affordability as a significant challenge, with costs for general MCED tests ranging from approximately Rs. 13,000 to Rs. 60,000. For the Shield MCD test to achieve widespread adoption and impact public health effectively, pricing strategies will need to address the affordability gap in a price-sensitive market like India. Researchers continue to gather more evidence on multi-cancer early detection blood tests. Fresh global evidence, including findings from one of the largest real-world studies conducted in six Asian countries, is anticipated to be presented at the American Society of Clinical Oncology (ASCO) Breakthrough meeting. These studies aim to answer crucial questions regarding who should undergo such testing, how often it should be done, and its ultimate impact on reducing cancer deaths. Long-term follow-up studies and cost-effectiveness analyses are currently underway to further solidify the role of these innovative tests in comprehensive cancer care strategies. Overall, the launch of the Shield MCD test in India represents a pivotal moment in the country's fight against cancer. By offering a convenient and accessible early detection method, the collaboration between Zydus Lifesciences and Apollo Hospitals, backed by Guardant Health's technology, holds the promise of improving patient outcomes and significantly contributing to India's public health goals.

Frequently Asked Questions

Read Full Story on Quick Digest